Announcements Trials
Browse Landscape

Phase

Phase 2 2

Status

Recruiting 1Active not recruiting 1

Sponsor Class

NIH 2OTHER 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Head & Neck 2Sarcoma 1Gynecologic 1Genitourinary 1Gastrointestinal 1Endocrine 1Dermatologic 1CNS 1

Conditions

Melanoma 17Neoplasm Metastasis 5Lymphoma, Non-Hodgkin 5Leukemia, Myeloid, Acute 5Hodgkin Disease 5Sarcoma 4Precursor Cell Lymphoblastic Leukemia-Lymphoma 4Neuroblastoma 4Lymphoma 4Leukemia, Lymphocytic, Chronic, B-Cell 4Carcinoma, Renal Cell 4Burkitt Lymphoma 4Uveal Melanoma 3Uterine Cervical Neoplasms 3Prostatic Neoplasms 3Myelodysplastic Syndromes 3Lymphoma, Mantle-Cell 3Lymphoma, Large-Cell, Immunoblastic 3Lymphoma, Large B-Cell, Diffuse 3Lymphoma, Follicular 3Hematologic Neoplasms 3Gliosarcoma 3Carcinoma, Merkel Cell 3Carcinoma, Basal Cell 3Vulvar Neoplasms 2Urogenital Neoplasms 2Urinary Bladder Neoplasms 2Urethral Neoplasms 2Thyroid Neoplasms 2Seminoma 2

Interventions

Specimen Handling 6Nivolumab 6Magnetic Resonance Spectroscopy 6Platinum 4Cisplatin 41,2-diaminocyclohexaneplatinum II citrate 4Gemcitabine 3Carboplatin 3Ipilimumab 2Immunoglobulin G 2Disulfides 2CTLA-4 Antigen 2Biopsy 2relatlimab 1fluciclovine F-18 1cemiplimab 1cabozantinib 1atezolizumab 1X-Rays 1Transurethral Resection of Bladder 1Radiotherapy 1Radiation 1Phantoms, Imaging 1Docetaxel 1Cetuximab 1Bevacizumab 1(225)Ac-DOTA-c(RGDyK) 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
NIH × Nasopharyngeal Carcinoma × Ipilimumab × Clear all
NCT02834013 2026-06-03

Nivolumab and Ipilimumab in Treating Patients With Rare Tumors

National Cancer Institute (NCI)

Phase 2 Active not recruiting
798 enrolled
CNSDermatologicEndocrineGastrointestinalGenitourinaryGynecologicHead & NeckSarcoma

Nasopharyngeal Carcinoma, Bile Duct Neoplasms, Carcinoma, Basal Cell, Adenocarcinoma, Bronchiolo-Alveolar, Adenocarcinoma, Mucinous, Carcinoma, Transitional Cell, Carcinosarcoma, Chordoma, Carcinoma, Adenoid Cystic, Fibroma, Gallbladder Neoplasms, Hemangiosarcoma, Mouth Neoplasms, Paget Disease, Extramammary, Paraganglioma, Paranasal Sinus Neoplasms, Parathyroid Neoplasms, Pheochromocytoma, Pseudomyxoma Peritonei, Somatostatinoma, Thyroid Neoplasms, Vulvar Neoplasms, Desmoid Tumors, Seminoma, Carcinoma, Acinar Cell, Adrenocortical Carcinoma, Carcinoma, Endometrioid, Cholangiocarcinoma, Cystadenocarcinoma, Mucinous, Cystadenocarcinoma, Serous, Carcinoma, Giant Cell, Neurofibrosarcoma, Gestational Trophoblastic Disease, Rare Diseases, Gastrointestinal Stromal Tumors, Perivascular Epithelioid Cell Neoplasms

NCT05904080 2026-05-18

Testing Nivolumab and Ipilimumab Immunotherapy With or Without the Targeted Drug Cabozantinib in Recurrent, Metastatic, or Incurable Nasopharyngeal Cancer

National Cancer Institute (NCI)

Phase 2 Recruiting
50 enrolled
Head & Neck

Nasopharyngeal Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡